Alpha 2.0
Login Register
» Articles » PMID: 35213801

Recurrent SARS-CoV-2 RNA Detection After COVID-19 Illness Onset During Pregnancy

Overview
Journal Emerg Infect Dis
Specialty Infectious Diseases
Date 2022 Feb 25
PMID 35213801
Authors
Isabel Griffin
Kate R Woodworth
Romeo R Galang
Veronica K Burkel
Varsha Neelam
Samantha Siebman
Jerusha Barton
Susan E Manning
Kathryn Aveni
Nicole D Longcore
Elizabeth M Harvey
Van NGo
Deborah Mbotha
Sarah Chicchelly
Mamie Lush
Valorie Eckert
Paula Dzimira
Ayomide Sokale
Miguel Valencia-Prado
Eduardo Azziz-Baumgartner
Adam MacNeil
Suzanne M Gilboa
Van T Tong
Affiliations
Soon will be listed here.
Abstract

The Surveillance for Emerging Threats to Mothers and Babies Network conducts longitudinal surveillance of pregnant persons in the United States with laboratory-confirmed severe acute respiratory syndrome coronavirus 2 infection during pregnancy. Of 6,551 infected pregnant persons in this analysis, 142 (2.2%) had positive RNA tests >90 days and up to 416 days after infection.

Citing Articles

An human precision-cut lung slice platform provides insight into SARS-CoV-2 pathogenesis and antiviral drug efficacy.

Pechous R, Malaviarachchi P, Banerjee S, Byrum S, Alkam D, Ghaffarieh A J Virol. 2024; 98(7):e0079424.

PMID: 38940558 PMC: 11265413. DOI: 10.1128/jvi.00794-24.

SARS-CoV-2 Viral Replication Persists in the Human Lung for Several Weeks after Symptom Onset.

Tomasicchio M, Jaumdally S, Wilson L, Kotze A, Semple L, Meier S Am J Respir Crit Care Med. 2024; 209(7):840-851.

PMID: 38226855 PMC: 10995573. DOI: 10.1164/rccm.202308-1438OC.

Population-Based Linked Longitudinal Surveillance of Pregnant People and Their Infants: A Critical Resource for Emerging, Re-Emerging, and Persistent Threats.

Tong V, Woodworth K, Blau E, Shinde N, Akosa A, Gilboa S J Womens Health (Larchmt). 2022; 32(1):1-9.

PMID: 36454196 PMC: 9940319. DOI: 10.1089/jwh.2022.0419.

References
1.
Rodriguez-Grande C, Alcala L, Estevez A, Sola-Campoy P, Buenestado-Serrano S, Martinez-Laperche C . Systematic Genomic and Clinical Analysis of Severe Acute Respiratory Syndrome Coronavirus 2 Reinfections and Recurrences Involving the Same Strain. Emerg Infect Dis. 2021; 28(1):85-94. PMC: 8714233. DOI: 10.3201/eid2801.211952. View
2.
Cevik M, Tate M, Lloyd O, Maraolo A, Schafers J, Ho A . SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. Lancet Microbe. 2021; 2(1):e13-e22. PMC: 7837230. DOI: 10.1016/S2666-5247(20)30172-5. View
3.
Woodworth K, Reynolds M, Burkel V, Gates C, Eckert V, McDermott C . A Preparedness Model for Mother-Baby Linked Longitudinal Surveillance for Emerging Threats. Matern Child Health J. 2021; 25(2):198-206. PMC: 7780211. DOI: 10.1007/s10995-020-03106-y. View
4.
Tang X, Musa S, Zhao S, He D . Reinfection or Reactivation of Severe Acute Respiratory Syndrome Coronavirus 2: A Systematic Review. Front Public Health. 2021; 9:663045. PMC: 8226004. DOI: 10.3389/fpubh.2021.663045. View
5.
Abu-Raddad L, Chemaitelly H, Coyle P, Malek J, Ahmed A, Mohamoud Y . SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy. EClinicalMedicine. 2021; 35:100861. PMC: 8079668. DOI: 10.1016/j.eclinm.2021.100861. View